How Medical Device Manufacturers Should Evaluate a Paid Ads Partner

Overview

The gap is not talent. The two funnels run on different physics. Consumer wellness advertising optimizes toward a transaction that happens fast, in volume, with one decision maker who is also the payer. Device advertising optimizes toward a demo with a business buyer who has partners, a finance conversation, a compliance review, and an incumbent vendor already in the room. An agency that has only run the first kind brings those instincts to the second and produces activity that never turns into installed units.

This guide is for building your evaluation criteria before you take calls. It covers the structural differences that should shape the brief, the regulatory layer you carry that consumer brands do not, the channel questions that separate real capability from good slides, what measurement looks like when revenue lands months later and offline, and twelve questions worth more than a twenty page proposal. Device classification and claim limits are specific to your own clearances and documentation, so treat this as commercial orientation, not regulatory advice.

Consumer wellness versus capital equipment: the comparison that should shape your brief

| Dimension | Consumer wellness advertising | Device manufacturer advertising | | --- | --- | --- | | Conversion event | Booking, purchase, or membership signup on site | Demo request, spec pack download, distributor inquiry, or qualified call booked | | Sales cycle length | Days to a few weeks, often same session | Months, spanning multiple budget conversations and a financing decision | | Decision unit | One person, also the payer and the end user | A buying group: owner, clinical lead, practice manager, finance, sometimes group procurement | | Creative requirements | Lifestyle imagery, before and after framing, offer led promotions, patient social proof | Device in operation, clinical setting footage, throughput and workflow demos, operator testimony, spec clarity, trade show tie ins | | Attribution difficulty | Moderate: most value lands inside the platform window | High: revenue lands offline, months later, after calls the platform never sees | | Claim constraints | General advertising standards and platform policy | The device's own clearance or classification, plus platform policy, plus what distributors may repeat | | Audience size | Large, geographically defined, refreshable | Small, finite, often nameable. Possibly a few thousand qualified clinics |

Read the audience size row twice. If your addressable market is a finite set of clinics, you are not running a volume business. You are running a coverage and frequency business against a named universe. That changes budget logic, creative rotation, exclusion strategy, and what counts as saturation. An agency that treats it like a consumer market burns the same small audience with the same three ads until performance collapses, then calls the account fatigued.

Channel architecture: the three audiences your partner has to hold at once

Most device manufacturers are running some combination of three motions, and they are frequently in tension.

Direct to clinic demand generation is the motion everyone pitches. You advertise to clinic owners, drive demo requests, feed your own sales team. The hard part is targeting a professional audience accurately on platforms built for consumer signals, then qualifying hard enough that the sales team keeps taking the calls.

Distributor and dealer enablement is the motion almost nobody pitches, and it is often where the leverage sits. If you sell through a network, the job includes recruiting partners, supporting their local campaigns, arming them with compliant creative, and routing leads to the right territory without channel conflict. Ask whether the agency has built territory routing, co-branded asset libraries, or partner lead distribution. The answer is usually no, which is fine if they say so.

End consumer demand generation creates pull. When patients walk into clinics asking for your modality by name, you stop selling a device and start selling access to demand that already exists. It is a legitimate play, and also the one most likely to collide with claim constraints, since consumer facing copy drifts toward outcome language fastest.

The evaluation question is not whether an agency can do all three. It is whether they know the three need different creative, different measurement, and different budget logic, and whether they can tell you which to fund first. A partner who wants all three from day one is guessing. For how we think about sequencing, see our approach to wellness technology and device marketing.

The 12 questions to ask any prospective paid ads partner

1. Walk me through a program where the conversion event was a demo request rather than a purchase. What did you optimize toward, and what did you stop optimizing toward?
2. How do you push offline conversion data from a CRM back into the ad platforms, and who on your team has implemented it?
3. Our sales cycle runs months. How does that change your attribution windows, audience durations, and month over month reporting?
4. What do you need from our regulatory function before an ad goes live, and how do you review copy variations and AI assisted creative?
5. What is the difference between general wellness positioning and a claim tied to a clearance, and how does it show up in the ads you write?
6. How would you demonstrate a device in a clinical setting when we cannot show patient outcomes the way a consumer brand would?
7. Have you supported a dealer network, including territory based lead routing and co-branded asset governance?
8. Our qualified universe may be only a few thousand clinics. How does that change frequency, budget pacing, and exclusion strategy?
9. How do you qualify leads at the form stage, and would you raise our cost per lead to raise our opportunity rate?
10. How do you tie paid activity to trade shows, both before the show and in the weeks after?
11. What would you measure before we scale spend, and what result would tell you the thesis was wrong?
12. If we asked you to kill a channel that looked good on your report but produced no opportunities, how would you handle it?

A partner who cannot name a condition that would falsify their own plan has not built one.

How to structure a first engagement so it de-risks itself

Do not start with a full funnel build across three motions. Start with one motion, one segment, one defined conversion event, and give it long enough to produce stage data instead of lead data.

Define the qualified lead before launch. Write down the practice profile, the procedure volume, the location count, and the timeline that make a lead worth an hour of your sales team's time. Put those in the form. Accept that volume will drop.

Set up measurement before spend starts. CRM stages mapped, offline conversions flowing, source captured on every record. If that is not in place, delay the launch. Backfilling later never works, because the platform learns from what you fed it early.

In the first period, measure four things: demo request to held meeting rate, held meeting to qualified opportunity rate, profile fit of the accounts coming through, and time from first click to first held meeting. Those tell you whether targeting and message are right. Closed revenue is not available yet, and judging the program on it early kills something that was working.

Agree in advance what would cause you to scale, change the message, or stop, and write it down. The most expensive outcome here is not a failed test. It is a mediocre program nobody will call either way. Build creative production time into the plan too, because device creative needs a real clinic, a real operator, and a review step.